Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
PRTA
Prothena Corporation plc
Coramitug/ATTR amyloidosis represents a rare disease program, aligning with Prothena's rare disease portfolio.
|
$586.75M |
$10.88
+3.37%
|
|
CRMD
CorMedix Inc.
Melinta acquisition adds a diversified antibiotic portfolio expanding revenue mix into infectious disease therapeutics.
|
$582.25M |
$7.39
+3.65%
|
|
EMBC
Embecta Corp.
Embecta provides contract manufacturing/partner manufacturing services and potential co-packaging arrangements.
|
$572.26M |
$9.80
+3.05%
|
|
TECX
Tectonic Therapeutic, Inc.
TX45 is a recombinant fusion protein (Fc-relaxin) developed using TECX's GEODe platform, fitting the Recombinant Proteins & Enzymes category.
|
$552.32M |
$29.46
-0.74%
|
|
RLMD
Relmada Therapeutics, Inc.
NDV-01 is Relmada's lead oncology candidate targeting non-muscle invasive bladder cancer (NMIBC).
|
$548.54M |
$7.48
+6.86%
|
|
ENGN
enGene Holdings Inc.
engGene's core platform is non-viral gene therapy delivery (DDX platform) and its lead asset is a gene therapy product, placing it squarely in Gene Therapy.
|
$540.57M |
$8.04
-0.43%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$539.85M |
$10.00
-0.99%
|
|
ABSI
Absci Corporation
Absci's core platform is an Antibody Discovery Platform combining AI design with high-throughput wet-lab validation (lab-in-the-loop) for de novo antibody generation.
|
$538.33M |
$3.59
+11.15%
|
|
ALLO
Allogene Therapeutics, Inc.
Direct product category: off-the-shelf allogeneic CAR-T cell therapies (Allogene's core platform and pipeline).
|
$537.11M |
$2.38
+0.21%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$534.69M |
$13.98
+3.10%
|
|
ADCT
ADC Therapeutics S.A.
ADCT's lead product ZYNLONTA is an antibody-drug conjugate (ADC), directly aligning with the Antibody-Drug Conjugates category.
|
$530.19M |
$4.29
-2.05%
|
|
AQST
Aquestive Therapeutics, Inc.
Aquestive's PharmFilm drug-delivery platform enables non-invasive, thin-film administration of complex molecules; Anaphylm and Libervant employ this platform.
|
$527.05M |
$4.33
+1.64%
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$515.37M |
$4.67
-6.87%
|
|
LYEL
Lyell Immunopharma, Inc.
Lyell’s lead program LYL314 is a CAR-T cell therapy product targeting cancer (CD19/CD20 dual-target), the core business.
|
$509.45M |
$23.98
+1.18%
|
|
LXEO
Lexeo Therapeutics, Inc. Common Stock
Company is focused on AAV-based gene therapies (LX2006, LX2020) delivering therapeutic genes — direct Gene Therapy business.
|
$504.34M |
$6.90
+4.86%
|
|
FLGT
Fulgent Genetics, Inc.
Contract Research Organization services for bioPharma.
|
$502.64M |
$16.29
+0.99%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$488.22M |
$8.48
+2.91%
|
|
ESPR
Esperion Therapeutics, Inc.
Directly sells/markets cardiovascular drugs (NEXLETOL, NEXLIZET).
|
$487.69M |
$2.04
-0.73%
|
|
DNA
Ginkgo Bioworks Holdings, Inc.
Antibody Discovery Platform reflects the antibody-focused tools and services offered.
|
$486.54M |
$8.04
+1.13%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$483.94M |
$5.96
-0.25%
|
|
RGNX
REGENXBIO Inc.
Core product category: gene therapy using NAV AAV platform.
|
$480.41M |
$9.49
+3.26%
|
|
BNTC
Benitec Biopharma Inc.
BB-301 is an AAV-based gene therapy leveraging gene silencing and wildtype replacement, aligning with Gene Therapy.
|
$476.78M |
$13.99
+3.94%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$476.50M |
$7.50
+2.11%
|
|
MYGN
Myriad Genetics, Inc.
Companion diagnostics—biomarker-based tests that stratify patients for targeted therapies; aligns with Myriad's genetic tests.
|
$473.53M |
$5.08
+1.70%
|
|
ZVRA
Zevra Therapeutics, Inc.
Zevra focuses on rare-disease therapeutics (NPC, UCD, VEDS) and related pipeline assets, core to rare disease biotech.
|
$466.48M |
$8.48
+2.05%
|
|
EBS
Emergent BioSolutions Inc.
EBS directly develops and manufactures vaccines and vaccine-derived MCMs (BioThrax, ACAM2000, TEMBEXA) for government/public health programs.
|
$462.70M |
$8.81
+2.20%
|
|
ASMB
Assembly Biosciences, Inc.
Assembly Biosciences develops small-molecule antiviral therapeutics, including HSV helicase-primase inhibitors, HDV entry inhibitors, HBV capsid assembly modulators, and NNPI programs.
|
$462.49M |
$29.10
-0.75%
|
|
ACRS
Aclaris Therapeutics, Inc.
Company's focus is on immuno-inflammatory diseases, aligning with Immunology Therapeutics.
|
$460.47M |
$4.25
+6.78%
|
|
FULC
Fulcrum Therapeutics, Inc.
Fulcrum's lead asset pociredir is an oral small molecule therapeutic intended to induce HbF in SCD.
|
$448.64M |
$8.29
+3.82%
|
|
AVIR
Atea Pharmaceuticals, Inc.
Atea's lead program comprises antiviral small-molecule therapeutics targeting HCV.
|
$448.45M |
$5.74
+0.61%
|
|
VSTM
Verastem, Inc.
Company is a oncology-focused biotech developing and commercializing cancer therapeutics.
|
$439.39M |
$6.58
+3.71%
|
Showing page 11 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
